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Abstract: Expression of the kallikrein-related peptidase 
7 (KLK7) is dysregulated in ovarian cancer. We assessed 
KLK7 expression by ELISA and quantitative immunohisto-
chemistry and analyzed its association with clinicopatho-
logical parameters and patients’ outcome. KLK7 antigen 
concentrations were determined in tumor tissue extracts 
of 98 ovarian cancer patients by ELISA. For analysis of 
KLK7 immunoexpression in ovarian cancer tissue micro-
arrays, a manual quantitative scoring system as well as a 
software tool for quantitative high-throughput automated 
image analysis was used. In immunohistochemical analy-
ses, expression levels of KLK7 were not associated with 
patients’ outcome. However, in multivariate analyses, 
KLK7 antigen levels in tumor tissue extracts were signifi-
cantly associated with both overall and progression-free 
survival: ovarian cancer patients with high KLK7 levels 
had a significantly, 2-fold lower risk of death [hazard 
ratio (HR) = 0.51, 95% confidence interval (CI) = 0.29–0.90, 
p = 0.019] or relapse [HR = 0.47, 95% CI = 0.25–0.91, p = 0.024), 
as compared with patients who displayed low KLK7 levels. 
Our results indicate that – in contrast to earlier findings 
– high KLK7 antigen levels in tumor tissue extracts may 
be associated with a better prognosis of ovarian cancer 
patients.
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Introduction
Numerous studies have focused on improved understand-
ing of the underlying tumor biology in ovarian cancer and 
biomarkers associated with this fatal disease  (Cannistra, 
2004; Yoshida et al., 2009; Swisher et al., 2012). However, 
for both early and advanced ovarian cancer, clinical, histo-
morphological, and tumor biological biomarkers useful 
for diagnosis, prognosis, and/or therapy response predic-
tion are in short supply (Rosen et al., 2005). Cancer bio-
markers that would reliably predict the risk of an ovarian 
cancer patient to experience untimely disease recurrence 
followed by early death or response to preoperative, adju-
vant, or palliative therapy are urgently needed (Bast et al., 
2005). In this respect, tumor-associated proteases such 
as several of the members of the serine protease-type 
kallikrein-related peptidase family of genes (KLK1–15), 
located on chromosome 19q13.3-4, may function as tumor 
biomarkers in ovarian cancer (Yousef and Diamandis, 
2009; Seiz et al., 2012).
Only a few other established tumor biological markers 
do serve as cancer biomarkers for this kind of disease, the 
most important being the serum marker CA125 encoded 
by the MUC16 gene (Whitehouse and Solomon, 2003). 
Serum CA125 half-life was reported by various authors 
to be an independent prognostic factor for the survival 
of patients with advanced epithelial ovarian cancer 
and treated with chemotherapy. Uzunoglu et  al. (2013), 
however, are favoring the use of CA125 antigen deter-
mined at different times during the chemotherapy cycles 
to assess response to  chemotherapy and to predict clinical 
outcome of the ovarian cancer patients. Besides that, the 
serum-based OVA1 test (consisting of CA125, transferrin, 
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β2-microglobulin, apolipoprotein A1, and prealbumin) as 
well as the ROMA score (Risk of Malignancy Algorithm, 
consisting of human epididymis protein HE4, CA125, and 
menopausal status) can help to evaluate the likelihood that 
a woman’s ovarian tumor mass is malignant or benign and 
then support the clinician’s decision whether to transfer 
the patient to a gynecological oncologist for surgery (Yip 
et al., 2011). Yet, although any of these factors additionally 
to CA125 are considered valuable biomarkers for ovarian 
cancer detection or disease recurrence monitoring, none 
of these single markers was regarded as suitable for pre-
diction of ovarian cancer prognosis (Høgdall et al., 2010; 
Clarke et al., 2011; Kim et al., 2012; Macuks et al., 2012).
Recent studies suggest that several members of the KLK 
family, in conjunction with other histo-/biomarkers, can be 
used to predict surgical success (Dorn et al., 2007); others, 
including KLK7, may be assessed to predict response to 
chemotherapy or overall and progression-free survival (OS 
and PFS, respectively) (Kishi et  al., 2003;  Kyriakopoulou 
et  al., 2003; Shan et  al., 2006; Oikonomopoulou et  al., 
2008; Psyrri et  al., 2008; Dong et  al., 2010; Dorn et  al., 
2011a,b).
KLK7, initially described as human stratum corneum 
chymotryptic enzyme, was first identified in the human 
skin (Hansson et al., 1994) and is supposed to be involved 
in the process of skin desquamation (Caubet et  al., 
2004). In addition to skin, in normal tissue, KLK7 is pre-
dominantly produced by the esophagus, kidney, lung, 
stomach, cervix uteri, ovary, and the vagina (Shaw and 
Diamandis, 2007) and is upregulated in tumor tissues of 
patients afflicted with cancer of the cervix uteri (Termini 
et al., 2010), colon (Talieri et al., 2009), pancreas (Avgeris 
et al., 2010), and ovary (Dorn et al., 2006, 2007; Shan et al., 
2006; Psyrri et al., 2008) and downregulated in prostate 
cancer (Xuan et  al., 2008), breast cancer (Holzscheiter 
et al., 2006; Mangé et al., 2008), and kidney cancer (Gabril 
et al., 2010).
KLK7 expression in normal and cancerous tissues has 
been determined at the mRNA level by microarray analysis 
(Hibbs et al., 2004) and quantitative PCR (Kyriakopoulou 
et al., 2003; Holzscheiter et al., 2006) and at the protein 
level by immunoenzymometric assays (Dorn et al., 2006; 
Shan et  al., 2006) and immunofluorescence techniques 
(Psyrri et al., 2008).
In the present study, we aimed at determining KLK7 
protein expression in ovarian cancer tissues applying two 
different quantitative approaches, ELISA and quantitative 
immunohistochemistry (IHC), using well-characterized 
antibodies to KLK7. KLK7 immunoreactivity was estimated 
manually and by an automated image analysis software 
(Conway et  al., 2008). We compared these findings with 
clinical and histomorphological parameters and related 
them to OS and PFS of the ovarian cancer patients.
Results
Characterization of the polyclonal antibody 
AF2624 directed to KLK7
In previous studies from our groups on different sets of 
ovarian cancer patients, KLK7 antigen levels were deter-
mined in ovarian cancer tissue extracts using a highly 
sensitive ELISA test format. There, it was shown that KLK7 
is highly overexpressed in malignant ovarian tumors 
compared with healthy or benign ovarian tissues (Dorn 
et al., 2006, 2007; Paliouras and Diamandis, 2006; Shan 
et al., 2006). The antibodies used in the KLK7-ELISA did 
not prove to be of use in staining of formalin-fixed, par-
affin-embedded tissue (data not shown). Therefore, we 
screened other antibodies directed to KLK7 for the poten-
tial use in IHC and selected the highly specific, affinity-
purified polyclonal goat IgG antibody (pAb) AF2624 (R&D 
Systems, Wiesbaden, Germany).
To validate the antibody, we analyzed the specific-
ity of pAb AF2624 using Western blot analysis (Figure 1). 
Purified human KLK1 as well as recombinant human pro-
forms of KLK2-15 (∼1 μg each) were subjected to 12% SDS-
PAGE, blotted onto a PVDF membrane, then reacted with 
pAb AF2624, and subsequently visualized by reaction 
with an HRP-labeled antibody to goat IgG. Pro-KLK7 was 
the single antigen to show reactivity, thus indicating the 
specificity of the selected antibody. The proper transfer of 
Figure 1 Characterization of polyclonal antibody AF2624 directed to pro-KLK7.
Analysis of antigen-binding specificity of pAb AF2624 directed to recombinant KLK7 by Western blot analysis. Only pro-KLK7, with an appar-
ent molecular mass of approximately 26 kDa, but no other recombinant (pro-)KLKs, displayed immunoreactivity.
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KLK proteins onto the membrane was verified by reaction 
with an antibody directed against the C-terminally located 
Tag100 epitope present in pro-KLK3-15 (Seiz et  al., 2012, 
data not shown).
To further characterize the KLK7-directed antibody, 
we used different tissues with a known KLK7 expres-
sion level for IHC. In previous studies, KLK7 immunoex-
pression has been demonstrated in various tissues with 
highest staining intensity in the skin. Using pAb AF2624, 
and in line with previous findings, we in fact observed 
high immunoexpression in the stratum corneum of the 
skin, moderate expression in normal breast tissue, and 
low expression in skeletal muscle and benign ovarian 
tumor tissue (Figure 2).
Comparison of KLK7 levels by Western 
blotting, IHC, and ELISA
To further compare the different techniques of Western 
blot analysis, ELISA, and IHC for KLK7 expression, we 
randomly selected tissue specimens from nine ovarian 
cancer patients with either low (n = 5) or high (n = 4) 
KLK7 antigen levels as assessed by ELISA and analyzed 
these samples by Western blot analysis as well. Here, we 
observed reactivity of pAb AF2624 with a protein doublet, 
with an apparent molecular weight of about 32 and 30 
kDa, respectively (Figure 3A). These two bands may well 
Skin Breast
Skeletal muscle Benign ovarian tumor
Figure 2 Immunohistochemical staining of KLK7 in normal and 
benign tissues.
Strong KLK7 expression is observed in the outer layer (stratum 
corneum) of the skin, moderate staining in normal breast tissue, 
low staining in skeletal muscle, and no KLK7 immunoexpression in 
cystoma, a benign tumor of the ovary.
A
B
Figure 3 Analysis of the protein expression pattern of KLK7 in 
ovarian cancer by Western blot analysis and IHC.
(A) Ovarian cancer detergent-released tissue extracts assessed 
for KLK7 antigen expression by Western blot analysis. Samples 
showing high or low antigen levels by KLK7-ELISA were analyzed 
by Western blot analysis. The ELISA values (ng KLK7/mg total 
protein) of the samples were the following: 504, 20.32; 426, 
9.01; 427, 22.29; 436, 16.89; 485, 0.21; 825, 0.37; 433, 0.86. The 
antigen levels in the tumor extracts of 503 and 416 were below 
the lower detection limit of the KLK7-ELISA (0.2–10 ng/ml). pAb 
AF2624 showed reactivity with a protein doublet, with an appar-
ent molecular weight of 32 and 30 kDa, probably corresponding 
to pro-KLK7 and activated KLK7, respectively. The intensity of 
the two bands corresponds well with the classification high and 
low KLK7 by ELISA. For the estimation of the loading of the gel 
and protein transfer to the membrane, the blots were addition-
ally reacted with an antibody directed to GAPDH (lower panel). 
(B) Paraffin-embedded, formalin-fixed ovarian cancer tissues 
preselected by ELISA (high vs. low KLK7 protein expression) as 
assessed by IHC. Note that high KLK7 antigen content (504, 426, 
427, and 436) matches with pronounced cytoplasmic staining of 
tumor cells and absence of stromal cell staining; low ELISA KLK7 
antigen content (485, 503, 825, 416, and 433) is compatible with 
a faint cytoplasmic staining of tumor cells and absence of stromal 
cell staining (scale bar: 50 μm).
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correspond to pro-KLK7 and activated KLK7, respectively, 
as active KLK is generated by clipping off the short N-ter-
minal pro-peptide of the KLK7 zymogen (corresponding to 
seven amino acids). The intensity of the two bands cor-
responds well with the classification high and low KLK7 
levels as assessed by ELISA (for ELISA values see Figure 3).
Then, tissue microarray sections of the selected cases 
were stained with pAb AF2624 using the Dako EnVision 
method (Dako, Hamburg, Germany). Again, in these 
cases, pAb AF2624 reactivity in immunohistochemical 
staining showed to be high and low, respectively, concord-
ant with the KLK7 antigen concentration determined by 
ELISA (Figure 3B).
Relationship between KLK7 expression 
levels in ovarian cancer tissue
We then aimed at comparing the well-established KLK7-
ELISA format with IHC using the sensitive and specific pAb 
AF2624 in 98 ovarian cancer patients. In ovarian cancer 
tissue, we observed prominent staining of tumor cells but 
less staining of stromal cells. Because both stromal and 
tumor cells express KLK7 in ovarian cancer tissue, we 
aimed at analyzing the expression pattern individually 
in these cell types. There are several examples in the lit-
erature demonstrating a prognostic impact of the expres-
sion pattern of a given biomarker either present in stromal 
or tumor cells (see, e.g., Kotzsch et al., 2010; Seiz et al., 
2012). Therefore, for the evaluation of observer-assisted 
analysis of KLK7 immunostaining, a quantitative score 
based on staining intensity and percentage of positively 
stained cells was designed (see Materials and methods) 
for tumor cell (KLK7-RT) and stromal cell (KLK7-RN) KLK7 
expression. The mean KLK7-RT and KLK7-RN scores values 
of two or three cores from each tumor sample and the 
summary score of both score values (KLK7-RT+RN) were 
used for statistical analyses. In addition, another method 
for analysis of total KLK7 expression, namely automated 
image analysis of KLK7 immunostaining utilizing positive 
pixel algorithms (see Materials and methods section) was 
performed. Again, after analyzing two or three cores from 
each tumor sample, the mean score value (KLK7-AV) of the 
readings was used for statistical calculation.
A distinctly elevated KLK7 expression was observed 
in tumor cells compared with stromal cells in tumor 
tissue: the mean score value of KLK7-RT was higher (5.5, 
range 0–30) than that of KLK7-RN (1.9, range 0–10). The 
frequency of score values greater than zero was much 
higher for tumor cells (71 vs. 27 negative) compared with 
stromal cells (24 vs. 74 negative). The overall KLK7-RT+RN 
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Figure 4 Association of KLK7 immunoexpression and antigen levels 
in tumor tissue.
Box plot analyses of the association of KLK7 immunoexpres-
sion in tumor cells (KLK7-RT) and KLK7-ELISA after grouping the 
KLK7-RT values by the 33rd and 66th percentiles into the category 
high, medium, and low. Significant differences of KLK7-ELISA 
values between the  ≥  66 group and the two other groups were 
observed (p = 0.001, Kruskal-Wallis test; groups  ≥  66 vs.  ≥  33– < 66, 
p = 0.012;  ≥  66 vs.  < 33, p < 0.001;  ≥  33– < 66 vs.  < 33, p = 0.252, Mann-
Whitney U-test).
and KLK7-AV score values ranged from 0 to 40 (mean 7.4) 
and from 63 to 5201 (mean 1126), respectively. The mean 
KLK7-ELISA (KLK7-E) value was 5.5 ng/mg protein (range 
0–45.9).
We found a moderate but statistically significant cor-
relation between KLK7-RT and KLK7-RN values (rs = 0.46, 
p < 0.001). A strong, significant correlation was observed 
among KLK7-RT, KLK7-RN, and KLK7-RT+RN score values 
(KLK7-RT/KLK7-RT+RN, rs = 0.89, p < 0.001; KLK7-RN/KLK7-
RT+RN, rs = 0.70, p < 0.001). Furthermore, KLK7-AV score 
values were significantly correlated with KLK7-RT (rs = 0.74, 
p < 0.001), with KLK7-RN (rs = 0.54, p < 0.001) and with the 
overall KLK7-RT+RN score values (rs = 0.75, p < 0.001).
Next, we evaluated the relationship between KLK7 
immunoexpression and KLK7 antigen levels in tumor 
tissue extracts by ELISA (KLK7-E). The KLK7-E concentra-
tion was only weakly (but significantly) correlated with 
KLK7-RT, KLK7-RN, KLK7-RT+RN, and KLK7-AV immu-
noscore values (rs = 0.39, p < 0.001; rs = 0.30, p < 0.01; rs = 0.30, 
p < 0.001; rs = 0.27, p < 0.01). When we grouped the KLK7 
immunoexpression in tumor cells (KLK-RT) into three cat-
egories (by the 33rd and 66th percentiles) and analyzed 
their relation to KLK7-ELISA, applying box plot analyses, 
significant differences of KLK7-ELISA values between 
the groups were observed (p = 0.001, Kruskal-Wallis test; 
Figure 4). Because there may exist an a priori ordering of 
the three groups analyzed, additionally, the Jonkheere-
Terpstra test was used to test for associations. In fact, a 
highly significant positive association was found between 
KLK7 values and KLK-RT groups (p < 0.001).
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Association of KLK7 expression with  
clinicopathological parameters
As justified by the results depicted in Figure 4, for all 
statistical analyses, the 66th percentile of the immu-
noscore values was applied as cutoff to classify immu-
nohistochemical KLK7 expression as high ( > 66%) or low 
(0–66%): KLK7-RT, cutoff = 5 (KLK7-RT high with immu-
noscore  > 5.01: 30 cases, KLK7-RT low: 68 cases); KLK7-RN, 
cutoff = 0 (KLK7-RN high with immunoscore  > 0: 24 cases, 
KLK7-RN low: 74 cases); KLK7-RT+RN, cutoff = 6 (KLK7-
RT+RN high with immunoscore  > 6.01: 33 cases, KLK7-RT 
low: 65 cases); KLK7-AV, cutoff = 1100 (KLK7-AV high with 
immunoscore  > 1101: 33 cases, KLK7-AV low: 65 cases). 
Likewise, the KLK7-E concentrations were divided into 
groups with high or low antigen levels by the 66th percen-
tile (4.0 ng/mg protein; KLK7-E high with values  > 4.01: 33 
cases, KLK7-E low: 65 cases).
KLK7 values stratified into low and high expression 
groups by the 66th percentile were used for assessing the 
association of KLK7 with clinical and histomorphological 
parameters. The relationship between KLK7 immunoscore 
values and KLK7-E antigen levels – and relevant clini-
copathological parameters of ovarian cancer patients 
– is summarized in Table 1. High levels of KLK7-RT, 
KLK7-RT+RN, and KLK7-AV are related to the presence 
of residual tumor mass (p = 0.033, p = 0.010, and p = 0.018, 
respectively). Furthermore, a significant association was 
observed between high KLK7-RT+RN score values and 
high ascitic fluid volume (p = 0.004). In addition, high 
KLK7-AV values are associated with FIGO stage III/IV 
(p = 0.034), high KLK7-E concentrations with response to 
chemotherapy (p = 0.034), whereas high KLK7-RN values 
were strongly related to low nuclear grade G1+2 (p = 0.004) 
(Table 1).
Association of clinicopathological param-
eters and KLK7 expression with patient’s 
survival
The association of relevant clinicopathological param-
eters and KLK7 protein expression levels with OS and 
PFS is presented in Tables 2 and 3. All clinicopathologi-
cal variables included in the Cox model, such as FIGO 
stage I/II vs. III/IV nuclear grade G1/2 vs. G3/4, presence of 
residual tumor mass and ascitic fluid volume, but not age, 
were univariate predictors for OS in the ovarian cancer 
Table 1 Association between clinical/histomorphological characteristics of patients and tumor biological factors (n = 98).
Clinicopathological  
parameters
No. of 
patients
KLK7-RTa,b 
low/high
KLK7-RNa,b 
low/high
KLK7-RT+RNa,b 
low/high
KLK7-AVa,b 
low/high
KLK7-ELISAa 
low/high
Total no. of patients 98 68/30 74/24 65/33 65/33 65/33
Age NS NS NS NS NS
  ≤  60 years 60
  > 60 years 38
FIGO stage NS NS NS p = 0.034 NS
 I+II 21 18/3
 III+IV 77 47/30
Nuclear grade NS p = 0.004 NS NS NS
 G1+G2 37 22/15
 G3+G4 61 52/9
Residual tumor mass p = 0.033 NS p = 0.010 p = 0.018 NS
 0 mm 52 40/12 41/11 40/12
  > 0 mm 41 23/18 22/19 22/19
Ascitic fluid volume NS NS p = 0.004 NS NS
  ≤  500 ml 64 49/15
  > 500 ml 32 15/17
Response to CTX p = 0.052 NS NS NS p = 0.034
 No 13 12/1 12/1
 Yes 63 41/22 39/24
Bold values are significant results (p<0.005); values in italic/not bold are have missed significance. 
aχ2-test (cutoff point  > 66th percentile).
bKLK7 immunoreactivity scores (KLK7-RT: in tumor cells; KLK7-RN: in stromal cells; KLK7-RT+RN: addition of KLK7-RT and KLK7-RN score 
values; KLK7-AV.: immunoscore by automated image analysis).
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Table 2 Univariate Cox regression analysis to determine disease survival in patients with ovarian cancer (n = 98).
Clinicopathological 
parameters
No. of 
patients
OS PFS
HR (95% CI)a p-Value HR (95% CI)a p-Value
Total no. of patients 98
Age
  ≤  60 years 60 1
  > 60 years 38 1.49 (0.91–2.42) NS 1.26 (0.73–2.19) NS
FIGO stage
 I+II 21 1 1
 III+IV 77 4.89 (2.10–11.4)  < 0.001 7.98 (2.48–25.7)  < 0.001
Nuclear grade
 G1+G2 37 1 1
 G3+G4 61 1.88 (1.10–3.18) 0.020 1.64 (0.91–2.96) NS
Residual tumor mass
 0 mm 52 1 1
  > 0 mm 41 5.69 (3.28–9.87)  < 0.001 5.30 (2.91–9.63)  < 0.001
Ascitic fluid volume
  ≤  500 ml 64 1 1
  > 500 ml 32 3.35 (2.03–5.52)  < 0.001 2.85 (1.61–5.05)  < 0.001
KLK7-RTb,c
 Low 68 1 1
 High 30 1.36 (0.82–2.27) NS 1.53 (0.87–2.69) NS
KLK7-RNc
 Low 74 1 1
 High 24 1.02 (0.59–1.77) NS 0.83 (0.42–1.61) NS
KLK7-RT+RNb,c
 Low 65 1 1
 High 33 1.50 (0.91–2.46) NS 1.41 (0.80–2.48) NS
KLK7-AVb,c
 Low 65 1 1
 High 33 1.53 (0.92–2.53) 0.098 1.39 (0.78–2.47) NS
KLK7-ELISAb
 Low 65 1 1
 High 33 0.71 (0.42–1.20) NS 0.66 (0.36–1.20) NS
aHR (95% CI) of univariate Cox regression analysis.
bDichotomized in high and low levels by the 66th percentile (low: 0th–66th, high:  > 66th percentile).
cKLK7 immunoreactivity scores (KLK7-RT: in tumor cells; KLK7-RN: in stromal cells; KLK7-RT+RN: addition of KLK7-RT and KLK7-RN score 
values; KLK7-AV: immunoscore by automated image analysis).
cohort (Table 2). Likewise, in univariate analysis for PFS, 
all of the clinicopathological parameters, except age and 
nuclear grade, reached statistical significance (Table 2). 
Conversely, the expression level of KLK7 in tumor cells 
or stromal cells as detected by IHC, the combined overall 
score KLK7-RT+RN, and the KLK7-E values were not associ-
ated with patients’ outcome in univariate Cox regression 
analysis (Table 2).
Strikingly, in multivariate analysis, KLK7-E values, 
in addition to FIGO stage and residual tumor mass, were 
significantly associated with survival (Table 3). Ovarian 
cancer patients with high KLK7-E levels had a signifi-
cantly, 2-fold lower risk of death or relapse with a hazard 
ratio (HR) of 0.51 (95% CI = 0.29–0.90, p = 0.019) and 0.47 
(95% CI = 0.25–0.91, p = 0.024), respectively, as compared 
with patients who displayed low KLK7-E levels (Table 3).
In addition, we performed statistical analyses in 
the subgroup of patients with advanced ovarian cancer 
(FIGO stage III/IV; n = 77). Here, the clinical variables age 
(only for OS), presence of residual tumor mass, and high 
ascitic fluid volume were univariate predictors for both 
OS and PFS. Furthermore, we found a significant associa-
tion between low KLK7-E antigen levels in tumor tissue 
extracts and an increased risk of death for FIGO III/IV 
patients in univariate Cox regression analysis (Table 4). 
On the contrary, KLK7 immunoscore values were not sig-
nificantly related with OS and PFS in FIGO III/IV ovarian 
cancer patients.
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Table 3 Multivariate Cox regression analysis to determine the association of tumor biological factors with disease survival in patients with 
ovarian cancer (n = 91).
Clinicopathological 
parameters
No. of 
patients
OS PFS
HR (95% CI)a p-Value HR (95% CI)a p-Value
Total no. of patients 91
Age
  ≤ 60 years 57 1 1
  > 60 years 34 1.37 (0.81–2.30) NS 1.16 (0.64–2.10) NS
FIGO stage
 I+II 18 1 1
 III+IV 73 2.57 (0.95–6.99) 0.064 3.80 (1.10–13.2) 0.035
Nuclear grade
 G1+G2 34 1 1
 G3+G4 57 1.20 (0.69–2.08) NS 0.92 (0.50–1.70) NS
Residual tumor mass
 0 mm 51 1 1
  > 0 mm 40 3.59 (1.75–7.35)  < 0.001 3.43 (1.65–7.12) 0.001
Ascitic fluid volume
  ≤ 500 ml 63 1 1
  > 500 ml 28 1.14 (0.60–2.15) NS 1.15 (0.57–2.33) NS
KLK7-RTb,c
 Low 62 1 1
 High 29 1.12 (0.65–1.93) NS 1.21 (0.67–2.18) NS
KLK7-RNc
 Low 71 1 1
 High 20 0.62 (0.32–1.21) NS 0.58 (0.28–1.21) NS
KLK7-RT+RNb,c
 Low 62 1 1
 High 29 0.97 (0.56–1.68) NS 1.02 (0.55–1.88) NS
KLK7-AVb,c
 Low 61 1 1
 High 30 1.37 (0.76–2.47) NS 1.20 (0.63–2.26) NS
KLK7-ELISAb
 Low 60 1 1
 High 31 0.51 (0.29–0.90) 0.019 0.47 (0.25–0.91) 0.024
aHR (95% CI) of multivariate Cox regression analysis. Biological markers were separately added to the base model of clinical parameters: 
age, FIGO stage, nuclear grade, residual tumor mass, and ascitic fluid volume.
bDichotomized in high and low levels by the 66th percentile (low: 0th–66th, high:  > 66th percentile).
cKLK7 immunoreactivity scores (KLK7-RT: in tumor cells; KLK7-RN: in stromal cells; KLK7-RT+RN: addition of KLK7-RT and KLK7-RN score 
values; KLK7-AV: immunoscore by automated image analysis).
In multivariate Cox analysis for advanced ovarian 
cancer patients, the presence of residual tumor mass 
remained a strong, statistically significant parameter 
for both OS and PFS (Table 4). As already shown in the 
whole patient cohort, in multivariate analysis, high 
KLK7-E values were strongly associated with a longer OS 
(HR = 0.40, 95% CI = 0.22–0.73, p = 0.003) and PFS (HR = 0.45, 
95% CI = 0.23–0.87, p = 0.018). These findings were con-
firmed by Kaplan-Meier estimation; the association of 
KLK7-E levels with OS and PFS is visualized by the respec-
tive survival curves (Figure 5). All other analyzed clinical, 
histomorphological, and biological parameters as well as 
biological factors were not significantly related with OS 
and PFS in FIGO stage III/IV ovarian cancer patients (data 
not shown).
Discussion
This study aimed at examining KLK7 expression in 
ovarian cancer tissue and analyzing its association with 
the course of the disease. KLK7 has been described to be 
overexpressed in ovarian cancer compared with healthy 
ovarian tissue and benign ovarian tumors and to be asso-
ciated with more advanced and aggressive disease and 
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Table 4 Univariate and multivariate Cox regression analysis to determine the association of tumor biological factors with disease survival 
in FIGO III/IV ovarian cancer patients (n = 77 and n = 73, respectively).
Clinicopathological 
parameters
No. of 
patients
OS PFS
HR (95% CI)a p-Value HR (95% CI)a p-Value
Univariate analysis
Total no. of patients 77
Age
  ≤ 60 years 48 1 1
  > 60 years 29 1.82 (1.08–3.04) 0.023 1.47 (0.83–2.62) NS
Residual tumor mass
 0 mm 33 1 1
  > 0 mm 41 4.30 (2.39–7.73)  < 0.001 3.60 (1.93–6.69)  < 0.001
Ascitic fluid volume
  ≤ 500 ml 46 1 1
  > 500 ml 30 3.06 (1.81–5.19)  < 0.001 2.62 (1.45–4.73) 0.001
KLK7-ELISAb
 Low 51 1 1
 High 26 0.55 (0.31–0.95) 0.032 0.56 (0.30–1.05) 0.071
Multivariate analysis
Total no. of patients 73
Residual tumor mass
 0 mm 33 1 1
  > 0 mm 40 3.49 (1.68–7.22)  < 0.001 3.31 (1.59–6.90) 0.001
KLK7-ELISAb
 Low 47 1 1
 High 26 0.40 (0.22–0.73) 0.0030 0.45 (0.23–0.87) 0.018
aHR (95% CI) of multivariate Cox regression analysis. Biological markers were separately added to the base model of clinical parameters in 
the FIGO III/IV subgroup: age, nuclear grade, residual tumor mass, and ascitic fluid volume.
bDichotomized in high and low levels by the 66th percentile (low: 0th–66th, high:  > 66th percentile).
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Figure 5 Probability of OS and PFS of advanced ovarian cancer patients stratified by antigen levels in tumor tissue.
Advanced stage ovarian cancer patients (FIGO III/IV), with elevated KLK7 levels ( > 4.0 ng/mg protein) in tumor tissue, as assessed by ELISA, 
show significantly better OS (Kaplan-Meier analysis, p = 0.029) (A) and a trend for better PFS (p = 0.064) (B) than the group of patients with 
low KLK7 levels ( ≤  4.0 ng/mg protein).
poor outcome (Dong et  al., 2003, 2010; Kyriakopoulou 
et al., 2003; Bignotti et al., 2006; Shan et al., 2006; Zheng 
et  al., 2007; Psyrri et  al., 2008; Girgis et  al., 2012). Most 
findings, so far, have been acquainted by analyses of the 
KLK7 mRNA expression level or, on the protein level, by 
ELISA.
We first analyzed the performance of the commer-
cially available polyclonal antibody AF2624 to KLK7 by 
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Western blot analyses and, through this, excluded cross-
reactivity with the other 14 serine proteases of the human 
KLK family. Next, we used antibody AF2624 in IHC to eval-
uate KLK7 protein expression in various types of tissues. 
Overall, KLK7 immunoreactivity has been described to 
be cytoplasmatic, not tissue-specific, but with charac-
teristic expression patterns depending on the origin of 
the tissue. Glandular epithelia constitute the main sites 
of KLK immunoexpression; positive immunoreactivity in 
their secretions suggests that KLKs are secreted proteins 
(Petraki et al., 2006).
KLK7 is known to be primarily expressed in the skin, 
suitable to its supposed physiological role in desqua-
mation and keratinization processes, specifically in the 
stratum corneum, but also in endocrine sweat and apo-
crine glands (Petraki et al., 2006). This is in line with our 
findings. For breast tissue, moderate staining has been 
described by Petraki et  al. (2006), findings we could 
reproduce using pAb AF2624 as well. Mesenchymal tissue 
and benign ovarian tumors have been reported to show 
no or only weak staining for KLK7 (Dong et al., 2003). In 
line with these reports, we observed weak KLK7 protein 
expression when staining cystoma of the ovary or skeletal 
muscle specimens.
The major aims of our study were to compare the 
technique of observer-assisted, manual analysis with 
automated quantification of KLK7 immunostaining and 
to analyze the similarities and differences in results 
acquired by ELISA and Western blot. When applying 
these techniques to a chosen set of ovarian cancer speci-
mens with low and high KLK7 levels as determined by 
ELISA in tumor tissue extracts, Western blot analyses 
and IHC staining intensity were found to be concordant 
with the ELISA results. However, when analyzing KLK7 
antigen levels quantified in tumor tissue extracts by 
ELISA compared with KLK7 tissue immunoreactivity in 
all cases of the cohort (n = 98) using Spearman correla-
tion, association between KLK7-ELISA levels and KLK7 
immunoscore values is only moderate indicating that 
the different technical approaches can be compared, but 
with limitations.
The moderate association between KLK7-ELISA and 
KLK7-IHC values is not unique for this serine protease. 
In fact, such a weak correlation has been demonstrated 
for the serine protease urokinase-type plasminogen 
activator (uPA) as well (Lang et  al., 2013). One reason 
is that, for IHC, only a thin section of tumor tissue is 
investigated, whereas for the ELISA test, proteins are 
extracted from relatively large pieces of tumor tissue and 
then the protein of interest is determined in this tissue 
extract. A second reason could be the use of different 
KLK7 antibodies in ELISA and in IHC because the anti-
bodies applied in the ELISA test were not suitable for IHC 
staining.
Another aim of the study was to determine the clini-
cal impact of KLK7 expression levels to predict the course 
of the ovarian cancer disease. KLK7, among other KLKs, 
has been reported to be involved in ovarian tumor pro-
gression and to predict OS and PFS as well as surgical 
outcome and response to chemotherapy (Kyriakopoulou 
et al., 2003; Borgono and Diamandis, 2004; Shan et al., 
2006; Dorn et  al., 2007; Oikonomopoulou et  al., 2008; 
Psyrri et al., 2008; Dong et al., 2010). In our study, in Cox 
univariate and multivariate analysis, neither KLK7 IHC 
scores by observer-assisted analysis nor by automated 
quantification, showed statistically significant prognos-
tic impact. Thus, KLK7 IHC results (regardless of how 
they are assessed) are not useful for predicting the clini-
cal outcome of ovarian cancer patients. This finding is 
in line with reports regarding assessment of the clinical 
impact of the protease uPA and its inhibitor PAI-1: regard-
ing various types of cancer, quantitation of uPA and/
or PAI-1 is performed by ELISA and not by IHC (Schmitt 
et al., 2008).
Strikingly, however, at the multivariate level, KLK7-
ELISA (KLK7-E) values, in addition to the established 
prognostic clinical factors FIGO stage and residual 
tumor mass, were significantly associated with both OS 
and PFS. One possible explanation for the significance 
of KLK7 expression at the multivariate but not the uni-
variate level are differences in the number of patients 
included in the analyses, as some are lost for the mul-
tivariate analysis due to missing values (in our cohort, 
98 patients for univariate analysis, 91 for multivariate 
analysis; in the group of FIGO III/IV patients: 77 vs. 73). 
Apart of this, the prognostic effect of KLK7 could be mod-
ulated by the other variables included in the multivariate 
analysis. Ovarian cancer patients with high KLK7-E levels 
had a significantly 2-fold lower risk of death or relapse, 
as compared with patients who displayed low KLK7-E 
levels. This is in contrast to earlier findings, where high 
KLK7 levels were associated with more advanced disease, 
later stage, and shorter PFS as estimated by ELISA (Shan 
et  al., 2006), quantitative PCR (Kyriakopoulou et  al., 
2003), and immunofluorescence analysis (Psyrri et  al., 
2008).
However, contradictory findings have already been 
reported for KLK7 in breast cancer: Holzscheiter et  al. 
(2006) analyzed the expression of full-length KLK7 
mRNA encoding for the active protease in breast cancer 
tissue and found high levels of KLK7 to be a favora-
ble prognostic marker (for disease-free survival; as a 
Bereitgestellt von | Saechsische Landesbibliothek - Staats- und Universitaetsbibliothek Dresden (SLUB)
Angemeldet
Heruntergeladen am | 30.01.20 13:35
104      J. Dorn et al.: KLK7 in ovarian cancer tissue
continuous marker as well as using an optimized cutoff). 
In contrast to this, Talieri et  al. (2004) reported KLK7 
mRNA levels (full-length and variant) to be significantly 
lower in breast cancer patients of low stage (I/II) and 
with positive progesterone receptors and that patients 
with KLK7-positive tumors had a shorter disease-free 
and OS compared with patients with KLK7-negative 
tumors, as assessed by semiquantitative RT-PCR. A 
possible explanation for this discrepancy might be the 
fact that in the cohort analyzed by Talieri et al. (2004), 
most of the patients were subjected to adjuvant therapy, 
whereas the patients in the study of Holzscheiter et al. 
(2006) might disclose more the natural course of the 
cancer disease by being least influenced by postopera-
tive systemic treatments.
Our ovarian cancer cohort has been uniformly treated 
by adjuvant platinum-containing polychemotherapy, 
except in those cases where a polychemotherapy was 
not indicated (FIGO I) or not suitable due to the patient’s 
general condition. In contrast to this, only 30% of the 
patients included in the study by Kyriakopoulou et  al. 
(2003) were treated with carboplatin and only 16% with 
paclitaxel. Thus, a therapy effect analogous to the one 
hypothesized by Holzscheiter et  al. (2006) is possible. 
Furthermore, in the patient cohort analyzed by Shan et al. 
(2006), more patients were of earlier stage (30% FIGO I/
II, as compared with 20% FIGO I/II in our cohort), which 
translates into a decease rate of 50% in the cohort of Shan 
et  al. (2006) compared with 67% in our patient group. 
Nevertheless, the pathophysiological function of most of 
the KLKs including KLK7 in ovarian cancer is not clear and 
needs further investigation using patient samples from 
multiple institutions to be able to explain contradictory 
findings in different patient cohorts.
In summary, we report on the evaluation of a com-
mercially available antibody against KLK7 and its utility 
for IHC. The selected antibody AF2624 shows good con-
cordance with previous results when staining normal 
and benign tissues. The two IHC scoring methods applied 
for the estimation of KLK7 tissue expression (observer-
assisted and automated scoring by image analysis) prove 
to be comparable. Nevertheless, according to our results, 
scoring the KLK7 immunoreactivity in formalin-fixed par-
affin-embedded ovarian cancer tissue is not a measure to 
predict the clinical outcome of the ovarian cancer patients. 
KLK7 levels as assessed by ELISA were, however, found to 
be significantly associated with ovarian cancer patient’s 
outcome in the present study. Yet, contrary to earlier find-
ings (Kyriakopoulou et al., 2003; Dorn et al., 2006, 2007; 
Shan et al., 2006), in our cohort, high KLK7 levels in tumor 
tissue extracts are associated with prolonged OS and PFS. 
This might be explained by differences in the patient 
cohorts (tumor stage) as well as therapy effects.
Materials and methods
Patients
A total of 98 patients afflicted with ovarian cancer FIGO stage I–IV 
(International Federation of Gynaecology and Obstetrics) between 
1990 and 1999 were enrolled in a retrospective study conducted at 
the Department of Obstetrics and Gynaecology, Klinikum rechts der 
Isar, Technische Universität München, Munich, Germany. Standard 
surgical procedures were performed, including pelvic and para-
aortic lymphadenectomy and – if indicated – partial resection of the 
small and large intestine, peritonectomies, and upper abdominal 
surgery. In younger patients ( < 35 years) with tumor FIGO stage I, less 
radical surgery was performed to preserve patient fertility. All of the 
patients gave written informed consent for the use of tissue mate-
rial for scientific and teaching purposes. The study was approved by 
the local ethics committee. Following surgery, all patients received 
adjuvant treatment according to consensus recommendations at that 
time, including platinum-based chemotherapy. None of the patients 
received neoadjuvant therapy before surgery.
The median age of the patients at surgery was 57 years (range 
20–85 years). The median follow-up time was 57 and 32.5 months for 
OS and PFS, respectively (range 1–244  months after primary tumor 
resection for both). Clinical and histomorphological factors docu-
mented at the time of surgery included FIGO stage, nuclear grade, 
presence of residual tumor mass (defined as largest intra-abdominal 
tumor diameter left at the end of the operation), and ascitic fluid vol-
ume (estimated preoperatively by vaginal ultrasound) (see Table 1). 
Of the 98 ovarian tumors, 74 were of serous papillary histotype, 4 
endometrioid, 10 undifferentiated, 8 mucinous, and 2 clear cell types. 
During the follow-up period of the study, 52 (53.1%) of the patients 
relapsed and 66 (67.3%) died.
Preparation of tumor tissue extracts and 
KLK7-ELISA
Tissue extracts from primary tumors of ovarian cancer patients 
were prepared as described previously (Dorn et al., 2006). In brief, 
fresh tissue samples were collected during surgery, classified by a 
pathologist, and stored in liquid nitrogen. Deep-frozen specimens 
of 200–500  mg wet weight were pulverized and resuspended in 
Tris-buffered saline (TBS; 0.02 m Tris-HCl, 0.125 m sodium chlo-
ride, pH 8.5), containing 1% w/v Triton X-100 (all: Sigma, Munich, 
 Germany). After extraction and ultracentrifugation, the superna-
tant was collected, aliquoted, and stored in liquid nitrogen until 
further analysis. KLK7 antigen concentrations were determined in 
tissue extracts using a noncommercial in-house KLK7-ELISA for-
mat. The detection limit of this KLK7-ELISA is 0.2 to 20 ng/ml (Pal-
iouras and Diamandis, 2006). KLK7 antigen levels are expressed 
as nanograms per milligram of total protein. The protein content 
in tumor tissue extracts was determined using the BCA method 
(Pierce, Rockford, IL, USA).
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Western blot analysis
Samples were subjected to 12% SDS-PAGE, and the separated pro-
teins transferred onto PVDF membranes (Pall, Dreieich, Germany) 
using a semidry transfer device. Membranes were incubated for 
60  min at room temperature in PBS-T (phosphate-buffered saline, 
pH 7.4, containing 0.1% Tween 20) plus 5% w/v skim milk powder 
(Fluka, Munich, Germany). Subsequently, the blots were incubated 
overnight with polyclonal goat antibody AF2624 (R&D  Systems, 
Abingdon, UK) directed to purified NS0-derived recombinant 
human KLK7 (aa 23–252), diluted in the same buffer (final concentra-
tion: 0.2 μg/ml). After three washes, 10 min each, in PBS-T at room 
temperature, the binding of the antibodies to the target protein was 
visualized by incubation of the membrane with horseradish per-
oxidase-conjugated rabbit anti-goat IgG (#A5420; Sigma, Munich, 
Germany) diluted 10,000-fold in PBS-T plus 5% skim milk powder, 
followed by chemiluminescence reaction (Amersham Biosciences, 
Little Chalfont, UK). For apparent molecular mass determination, 
the Page-Ruler Plus prestained protein ladder was used as a stand-
ard (range 10–250 kDa; Fermentas Life Sciences, St. Leon-Rot, Ger-
many).
Tissue preparation, and microarray 
construction
Tissue samples were obtained during surgery, inspected by a pathol-
ogist from the Institute of Pathology of the Technische Universität 
München, immediately fixated in neutral-buffered formalin, and 
then embedded in paraffin. The technique of tissue microarray pro-
duction has been described in detail elsewhere (Seiz et  al., 2012). 
In brief, morphologically, most representative areas of the tissue 
were marked on the original hematoxylin/eosin-stained tissue sec-
tion. Using these sections for orientation, three cylindrical core tis-
sue punches of 1 mm in diameter were taken from the selected area 
of each individual paraffin-embedded ovarian cancer tissue block 
(donor block) and precisely mounted into a paraffin block (recipient 
block) using a manual tissue microarray device (Beecham Instru-
ments, Silver Springs, MD, USA). Sections of 2 μm thickness of the 
resulting tissue microarray blocks were transferred to surface-coated 
glass slides and deparaffinized. For the construction of the tissue 
microarray block, fixed tumor specimens from 98 ovarian cancer 
patients were available.
Immunohistochemistry
Tissue sections were dewaxed, rehydrated, and treated for antigen 
retrieval by pressure cooking (4 min, 120°C, 0.1 m citrate buffer, 
pH 6.0). After several washes with TBS (pH 7.6), endogenous per-
oxidase activity was quenched by incubating the tissue sections at 
room temperature for 5 min with endogenous enzyme block solution 
(#K5361; Dako, Hamburg, Germany). After washing with TBS, sec-
tions were incubated at 4°C overnight with the human KLK7-directed 
primary polyclonal antibody AF2624, diluted to a final concentra-
tion of 0.4 μg/ml in antibody diluent (Dako). After washing with 
TBS, mouse-anti-goat IgG (Jackson Immunoresearch, Baltimore, 
MD, USA) diluted in antibody diluent was applied to all tissue slides 
(30 min, room temperature). Following another washing step with 
TBS, sections were reacted with a dextran polymer conjugated with 
horseradish peroxidase and secondary antibodies with anti-rabbit 
and anti-mouse specificity (30 min, room temperature; EnVision; 
Dako). After an additional washing step, the chromogenic reaction 
was carried out (10 min, room temperature) using the peroxidase 
substrate 3,3′-diaminobenzidine tetrahydrochloride (DAB+; Dako), 
which forms a brown product at the site of enzyme reaction. Finally, 
counterstaining of the sections was performed with Meier’s hema-
toxylin. As a negative control, the primary antibody was omitted and 
replaced by TBS or by irrelevant antibodies.
Quantification of KLK7 immunostaining
For the evaluation of observer-assisted analysis of KLK7 immu-
nostaining intensity and tissue location, a quantitative score based 
on staining intensity and percentage of positive cells was created by 
inspecting at least two tissue cores from each case. KLK7 staining 
intensity was classified on a scale of 0 to 3 (0: no staining; 1: weak 
staining; 2: moderate staining; 3: strong staining). The percentage of 
positively stained cells was scored by cell count on a scale of 1–10, 
with grade 1: staining of  ≤  10% of cells; grade 10, with  > 90% of posi-
tive cells. Based on these scores, a final immunoreactivity score was 
created by multiplying the intensity score values with the cell posi-
tivity score values for each tumor cells (KLK7-RT) and stromal cells 
(KLK7-RN). In addition, an overall score was created by adding up the 
KLK7-RT and KLK7-RN score values (KLK7-RT+RN).
The Hamamatsu Nanozoomer HT system (Hamamatsu Photon-
ics, Herrsching, Germany) was used to capture digital images. For 
automated image analysis of KLK7 immunostaining in ovarian can-
cer tumor tissue specimens, the software product OpTMA (SlidePath, 
Dublin, Ireland) was used. OpTMA facilitates high-throughput auto-
mated image analysis utilizing positive pixel algorithms. The results 
are presented as quantitative data. The software fully automates the 
dearraying process of TMAs and then automatically associates tissue 
spots with intensity data. From each tumor sample, at least two cores 
were evaluated, and the mean score values (KLK7-AV) of the readings 
were used for statistical calculations.
Statistics
The levels of significance between continuous variables of tumor 
biological markers were calculated using Spearman rank correlation 
(rs). The relationship of biological marker expression levels (grouped 
according to the 66th percentile) with clinical and histomorphologi-
cal parameters was evaluated using the χ2-test. For survival analyses, 
the OS and PFS of ovarian cancer patients were used as follow-up end 
points. The association of KLK7 antigen values and of clinicopathologi-
cal factors with OS and PFS was analyzed using the Cox univariate and 
multivariate proportional hazards regression models and expressed 
as HR and its 95% confidence interval (95% CI). The multivariate Cox 
regression model was adjusted for known clinical prognostic factors in 
ovarian cancer patients: age, FIGO stage, nuclear grade, presence of 
residual tumor mass, and ascitic fluid volume. In subgroup analysis of 
FIGO III/IV patients, the clinical factors age, nuclear grade, presence 
of residual tumor mass, and ascitic fluid volume were used. Survival 
curves were generated by Kaplan-Meier analysis using log-rank tests to 
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test for differences. All calculations were performed using the StatView 
5.0 statistical package (SAS Institute, Cary, NC, USA). p-Values  ≤  0.05 
were considered statistically significant.
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